PRJNA662314
RESISTANCE-ASSOCIATED SUBSTITUTIONS AFTER TRIPLE THERAPY (SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR) TREATMENT FAILURES
Characterization of the RAS in patients before begin the triple therapy (SOF+VEL+VOXI) treatment, and they prevalence at the end of treatment.